Nearly 70 players from across the world presently claim to be engaged in the development and evaluation of therapeutic candidates

January 11, 2021
Kevin123987

Psychedelic substances have been demonstrated to interact with a variety of neurotransmitter pathways, including those involving serotonin, acetylcholine, norepinephrine, and dopamine. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of psychedelic substances. Further, experts believe that psychedelics, at appropriate doses, can be used to address some of the serious psychological implications associated with the COVID-19 pandemic.

 

 

To order this 250+ page report, which features 120+ figures and 135+ tables, please visit this link

 

 

The over USD 6.5 billion (by 2030) financial opportunity within the psychedelic therapeutics market has been analyzed across the following segments:

  • Target Disease Indication
  • Anxiety and Depression
  • Trauma
  • Pain Disorder
  • Sleep related Disorder

 

  • Origin of Psychedelic Substance
  • Natural
  • Synthetic

 

  • Type of Psychedelic Substance
  • Gamma-hydroxybutyrate
  • Ketamine
  • MDMA
  • Psilocybin

 

  • Route of Administration
  • Oral
  • Intranasal
  • Sublingual

 

  • Key Geographies
  • North America
  • Europe
  • Asia-Pacific

 

The Global Psychedelic Therapeutics Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Celon Pharma
  • iX Biopharma
  • MAPS Public Benefit
  • MindMed
  • Janssen Pharmaceuticals
  • Jazz Pharmaceutical

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction
  3. Market Landscape: Psychedelic Therapeutics
  4. Company Profiles
  5. Clinical Trial Analysis
  6. Clinical Trial Site Analysis
  7. Key Opinion Leader (KOL) Analysis

 

  1. Academic Grants Analysis
  2. Partnerships and Collaborations
  3. Mergers and Acquisitions
  4. Market Forecast and Opportunity Analysis
  5. Concluding Remarks
  6. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Article Categories:
HEALTH

Leave a Comment